Our research
The Enzymatica Research Journey
Numerous clinical and in vitro studies have been performed over the years supporting the clinical benefits of ColdZyme and showing the effective device mechanism behind these benefits.
Stage 3Proof of Concept: Broader Upper Respiratory Tract Infections
Measuring protective effectiveness against a broadened range of upper respiratory viruses, testing over 10 major airborne virus types and subvariants using real-world evidence.
New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms
Feb. 2025
Glen Davison, University of Kent, England and Doris Wilflingseder, Ignaz Semmelweis Institute and Vetmeduni Vienna.
Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load
Sept. 2024
Glen Davison, University of Kent, England
Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
Aug. 2024
Glen Davison, University of Kent, England
Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
Jun. 2024
Glen Davison, University of Kent, England
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat
Sept. 2023
Glen Davison, University of Kent, England
ColdZyme breaks viral infection cycle – significantly reducing influenza viral load
Aug. 2023
Doris Wilflingseder, Medical University of Innsbruck, Austria
ColdZyme® protects airway epithelia from infection with BA.4/5 | Respiratory Research | Full Text (biomedcentral.com)
Oct. 2022
Viktoria Zaderer, Stefanie Dichtl, Rosa Bellmann Weiler, Cornelia Lass Flörl, Wilfried Posch & Doris Wilflingseder
Inactivation of SARS CoV-2 and HCoV-229E in vitro by ColdZyme®
Oct. 2022
Gudmundsdottir Á, Scheving R, Lindberg F, Stefansson B
Effects of ColdZyme® Mouth Spray on upper respiratory tract infection URTI duration and viral load in endurance athletes.
May 2021
Glen Davison, University of Kent, Canterbury, UK
Stage 2Proof of Concept - Common Cold: In-Vivo
Assessingʼ viral load reduction scope and ability to protect people from the causes of the common cold, including its influence over symptoms and impact on human quality of life.
Coldzyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions - Randomised to control study for a 3-months period
Jun. 2020
Glen Davison, University of Kent, Canterbury, UK
Multi-symptom Relief and Improvement of Quality of Life - A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold
Apr. 2019
Fredrik Lindberg, Enzymatica AB, Lund, Sweden
Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff
Nov. 2017
Mats Clarsund
Enzymatica AB, Lund, Sweden
A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold
Nov. 2017
Mats Clarsund1, Marcus Fornbacke1, Lena Uller2, Sebastian L. Johnston3, Cecilia Ahlström Emanuelsson4
1Enzymatica AB, Lund, Sweden
2Unit of Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, Lund, Sweden
3Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, London, UK
4Department of Otorhinolaryngology, Skåne University Hospital, Lund, Sweden
Evaluation of ColdZyme Mouthspray against common cold in elderly care personnel
Feb. 2017
Mats Clarsund, Christina Bråkenhielm Persson
Stage 1Enzyme Exploration: In-Vitro
Evaluating barrier protection and its measured effectiveness in high need, vulnerable population groups, including effectiveness against the main cold-causing viruses.
A medical device forming a protective barrier that deactivates four major common cold viruses
Nov. 2017
Bjarki Stefanson, Augusta Gudmundsdottir, A. Clarsund